Research has found that weight-loss drugs such as Ozempic may help curb addictive behaviours, such as alcohol addiction. One ...

Summary: A new study suggests that two widely used Type 2 diabetes medications—GLP-1 receptor agonists and SGLT2 inhibitors—may help reduce the risk of Alzheimer’s disease and related dementias.

Dat zijn pillen met semaglutide (dezelfde werkzame stof als in de spuiten van Ozempic). Vallen zwaarlijvige mensen zonder diabetes er óók van af? Dat is met de huidige Rybelsuspillen, die je momenteel ...

Dementia is the UK's biggest killer, claiming more lives than heart attacks and strokes combined. Despite exhaustive research ...

A new study, published in JAMA Neurology, finds that people with type 2 diabetes who take two common anti-diabetes ...

Semaglutide — the powerful ingredient behind Wegovy and Ozempic — has long been hailed ... seems to be promising in reducing the risk of Alzheimer's disease and related dementias (ADRD)'.

Semaglutide is available as Wegovy and Ozempic injections, and also as Rybelsus tablets ... They had no diagnosis of ...

Instead, GLP-1 agonists may help protect the brain by reducing inflammation. Previous research has shown that these drugs can shift immune cells from a pro-inflammatory to an anti-inflammatory ...

Newsweek has contacted Ozempic manufacturer Novo Nordisk for ... GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias. JAMA Neurology.

In an April 14 announcement, the FDA stated that Novo Nordisk — manufacturer of Ozempic and Wegovy — notified the agency that ...